SPONSOR
Shanghai Junshi Bioscience Co., Ltd.
Total Trials
5
Recruiting
5
Phases
Phase 3, Phase 1, Phase 2, Phase 2, Phase 1
Conditions studied: Limited-stage Small Cell Lung Cancer (LS-SCLC)Advanced Solid TumorNon-small Cell Lung CancerNon-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid TumorAdvanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06095583 Phase 3
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06139211 Phase 1, Phase 2
Recruiting
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Advanced Solid Tumor
NCT06969027 Phase 2
Recruiting
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC
Non-small Cell Lung Cancer
NCT06839105 Phase 1
Recruiting
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
NCT07284134 Phase 3
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma